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Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world. The evolution and progression
of HNSCC are considered to result from multiple stepwise alterations of cellular and molecular pathways in squamous epithelium.
Recently, inhibitor of growth gene (ING) family consisting of ﬁve genes, ING1 to ING5, was identiﬁed as a new tumor suppressor
gene family that was implicated in the downregulation of cell cycle and chromatin remodeling. In contrast, it has been shown that
ING1 and ING2 play an oncogenic role in some cancers, this situation being similar to TGF-β. In HNSCC, the ING family has been
reported to be downregulated, and ING translocation from the nucleus to the cytoplasm may be a critical event for carcinogenesis.
In this paper, we describe our recent results and brieﬂy summarize current knowledge regarding the biologic functions of ING in
HNSCC.
1.Introduction
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer in the world. More than
500,000 new cases and the over 50% mortality rate annually
indicate a major health problem worldwide [1]. HNSCC
is a broad term that represents squamous cell carcinomas
that arise in the upper aero- and digestive tract, including
the larynx, the pharynx, and the oral cavity. These sites
form a functional and anatomic unit and share exposure to
the same etiological factors in carcinogenesis [1]. It is well
known that smoking and alcohol abuse are major risk factors
for HNSCC. Additionally, human papillomavirus (HPV)
infection is another implicated risk factor, in particular for
oropharyngeal SCC [2, 3].
The evolution and progression of HNSCC are con-
sidered to result from multiple stepwise alterations of
cellular and molecular pathways in the squamous epithelium
[4]. Although lifestyle factors account for the majority of
HNSCCs, genetic alterations will cause some individuals to
be more sensitive to these environmental factors. Therefore,
screening for reliable genetic changes can provide a possible
opportunity to predict the risk of malignant transformation.
Tumor suppressor genes (TSGs) are often referred to as
“gatekeepers” because they prevent cancer development by
direct control of cell growth through genes such as p53 and
p16, the inactivation of which has been reported in many
tumors. The alterations of TSG, including mutation, loss
of heterozygosity (LOH), and microsatellite instability, are
considered to increase genetic susceptibility for malignant
transformation. Previous studies have identiﬁed that alter-
ations of p53 and p16 are associated with the development
and progression of HNSCC [5–8]. Inhibitor of growth gene
(ING) family, a new candidate TSG class, is implicated in
cell cycle control, senescence, apoptosis, DNA repair, and
chromatin modeling. The loss or downregulation of ING
expression has been observed in HNSCC. In this paper, we
summarized current knowledge on the biological functionof
ING family members and their status in the tumorigenesis of
HNSCC.
2. ING GeneFamily
ING1, the ﬁrst member of the ING family, was discovered
through a subtractive hybridization assay between normal
mammary epithelium and breast cancer cell lines and was2 Journal of Oncology
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Figure 1: Structure of ING proteins in Homo sapiens. Each ING protein with its name and encoding major variants is listed on the left. The
characterized domain composition, approximate location, is shown on the right. All ING proteins contain three conserved regions, a PHD
(plant homeodomain), NLS (nuclear localization signal), and NCR (novel conserved region) from C-terminal region to N-terminal region.
An LZL (leucine zipper-like domain) is present in ING2-5. p33ING1b also have a PIP (PCNA-Interacting Protein Motif) domain through
which it binds to PCNA following UV irradiation, a PBD (partial bromodomain) which commonly found in chromatin-associated protein,
and an LID (Lamin Interaction domain). p33ING1b binds to lamin A/HDAC complexes via LID to maintain its levels and biological function
in nucleus. Additionally, phosphorylation sites were found at serine 199 of p33ING1b. 14-3-3 bind to phosphorylated serine 199 result in
translocation of p33ING1b from the nucleus to the cytoplasm.
shown to play a role in neoplastic transformation [9]. Sub-
sequently, four other members of ING family, ING2, ING3,
ING4,a n dING5, were identiﬁed by computer homology
searches and were shown to have 32 to 76% DNA sequence
homology with ING1 [10–13]. The ING g e n e se a c hm a p p e d
to independent chromosomes: 13q34, 4q35, 7q31, 12p13.3,
and 2q37.3. All of the ING genes except ING3 localize to the
subtelomeric region of their respective chromosomes [14].
In addition, phylogenetic analysis identiﬁed that ING genes
are conserved in many species, including humans, mice, rats,
and yeast [15]. Alignment data show that the human and
mouse ING1 and ING3 proteins are 90% identical, whereas
the human and frog ING1 and ING3 proteins are 81% and
82% identical, respectively [16]. These data suggest that ING
genes play important roles in biological processes central to
life.
Most ING genes, excluding ING5, encode variants due
to diﬀerent promoters, exons, and alternative splice variants.
ING1 encodes four isoforms, p47ING1a,p 3 3 ING1b,p 2 4 ING1c,
and p27ING1d, which vary in mass between 24 and 47kDa.
Amongtheseisoforms,p33ING1b isthemostwidelyexpressed
in normal tissues [17]. ING2 encodes two isoforms. ING2a,
also called ING2 and ING1L, encodes a 280-aa protein
(p33ING2)thatshares58.9%similaritywithp33ING1b [10,11].
Recently, ING2b was identiﬁed and shown to be transcribed
from the middle of intron 1 of ING2a [18]. In addition,
ING3 encodes two isoforms, p47ING3 and p11ING3 [12].
ING4 encodes eight splice variants: ING4 v1, v2, v3, v4,
ING4ΔEx2, ΔEx3, ΔEx6A, and ΔEx6B [19, 20]. Only ING5
encodes a unique 240-aa protein (p28ING5)[ 13]. Splice
variants of ING proteins may compensate or compete with
each other and create more diversity in ING functions.
3. The Structureand Functionof ING Proteins
All ING proteins contain a plant homeodomain (PHD)
in the C-terminal region, a nuclear localization signal
(NLS), and a domain with an unknown function called the
novel conserved region (NCR) (Figure 1). The N-terminal
region of each ING protein is unique, which determines
the diﬀerential structures of ING proteins [21]. The PHD
domain, a zinc ﬁnger domain that binds histone H3 in
a methylation-sensitive manner, has been implicated in
chromatin remodeling [22]. Localization of ING proteins in
the nucleus is critical to their function [23]. The NLS targets
ING1 or other ING proteins to diﬀerent chromatin domains
in the nucleus and nucleolus in response to UV-induced
DNA damage [24]. Moreover, a leucine zipper-like (LZL)
domain is present in ING2–5 and has the potential to form aJournal of Oncology 3
hydrophobic face near the N-terminus of ING proteins [25].
Regarding its function, the LZL domain may be linked to
nucleotide excision repair and induction of apoptosis [26].
p33ING1b also carries three other domains. A proliferating
cellnuclearantigen-(PCNA-)interactingproteinmotif(PIP)
domainbindswithPCNAfollowingUVirradiation.Apartial
bromodomain (PBD) is commonly found in chromatin-
associated protein. A lamin interaction domain (LID) binds
with lamin A/HDAC complexes to maintain its levels and
biological function in the nucleus [27]. Recently, a phos-
phorylation site was found at serine 199 of p33ING1b. 14-
3-3 family proteins can bind to phosphorylated serine 199,
resulting in translocation of p33ING1b from the nucleus to the
cytoplasm [28].
4.PHDDomainand EpigeneticControl
Although the ING1 gene was cloned as a candidate gene for
tumor suppression, studies on the eﬀects of overexpression
ordownregulationofINGfamilyproteinsonvariouscellular
processes imply that the roles of the ING family genes in
tumorigenesis depend on cellular contexts; they could also
function as oncogenes in several aspects [29]. Therefore,
we ﬁrst described the functions of ING family proteins
in the epigenetic control of gene transcription and DNA
replication, details of which are now going to be elucidated.
Epigenetic controlof genetranscription is attained partly
by modulation of covalent modiﬁcations such as acetylation,
methylation, and/or phosphorylation of nucleosomal his-
tones within gene promoters [30]. ING proteins are known
to be a component of either histone acetylase (HAT) com-
plexes or histone deacetylase (HDAC) complexes that acti-
vate and inactivate gene transcription, respectively. p33ING1b
interacts with the mSin3/HDAC complex and also with
proteins associated with HAT activity such as p300, inducing
hyperacetylation of histones H3 and H4 [31–33]. Similarly,
ING2 complex with p300 also serves as a component of the
mSin3/HDAC complex [34–36]. ING3 associates with the
hNuA4/Tip60 HAT complex (nucleosome acetyltransferase
of H4 and Tat interactive protein, respectively; Tip60 is the
human homolog of yeast Esa1 HAT) that is responsible for
acetylation of histone H4 and H2A [36, 37]. Both ING4 and
ING5bindtop300[13],buttheyalsoassociatewithdiﬀerent
HATcomplexes.ING4isidentiﬁedasacomponentofafour-
subunit HAT complex containing HBO1 (histone acetyl-
transferase binding to origin recognition complex-1). HAT
and its cofactors JADE1/2/3 preferentially acetylate histone
H4 [36]. ING5 associates with MOZ (monocytic leukemic
zinc-ﬁnger protein)/MORF (MOZ related factor) HAT and
itscofactorBRPF(bromodomain-PHDﬁngerprotein)1/2/3,
resultinginincreasedspeciﬁcityforacetylationofhistoneH3
lysine 14 [36].
In turn, the PHD domains of ING family proteins were
recently shown to recognize trimethylated lysine 4 of histone
H3 (H3K4me3) that in many cases associates with active
gene transcription [30]. ING2 was ﬁrstly shown to bind
H3K4me3 via its PHD domain and stabilize the mSin3-
HDAC complex, resulting in repression of DNA damage-
induced transcription of cyclin D1 gene [22, 38]. ING1
also binds H3K4me3, and this binding is somehow neces-
sary for ING1-mediated DNA repair upon UV irradiation
as well as doxorubicin-mediated induction of apoptosis
in HT1080 ﬁbrosarcoma cells [39]. Intriguingly, cancer-
associated mutations in the ING1 PHD domain impaired
the binding of ING1 to H3K4me3 with concomitant loss
of functions in DNA repair and apoptosis, implying that
the binding of ING1 to H3K4me3 underlies its tumor-
suppressive functions [39]. Binding of ING4 to H3K4me3
anditsbiologicaloutcomeswereextensivelystudied[40–42].
Promoters bound by ING4 in response to DNA damage were
identiﬁedusingachromatinimmunoprecipitationtechnique
followed by whole genome promoter tiling arrays [42].
ING4 was recruited to its target promoters upon interaction
with H3K4me3 and increased the acetylation of histone
H3 lysine 9, leading to activation of gene transcription
and sensitization to cell death or inhibition of anchorage-
independent cell growth [42].
These compiled lines of evidence indicate that one basic
function of ING family proteins is to translate H3K4me3
markings on the nucleosomes into activation or inactivation
of gene transcription, DNA replication, or DNA repair
through the associated HAT or HDAC complex. Based on
this simple framework, further questions as follows may
be posed for the elucidation of the substance of “cellular
contexts” as described above, the same family member of
ING can complex with either HAT or HDAC. (1) What
determines the combination of ING proteins and HAT
or HDAC complexes and the ﬁnal outcomes? (2) What
modulates the inducible or constitutive binding of ING
proteins to H3K4me3 within gene promoters? (3) Do ING
family members compete for the binding to the same
H3K4me3 within a promoter or have some speciﬁcity for
it? To answer these questions, identiﬁcation of the genes
modulated by ING family proteins and side-by-side analyses
of transcriptional response of the gene and factors that
associate with ING proteins as made in [42] may be helpful.
5.INGand DNA Repair
The balance between cell growth and cell death is charac-
terized in tissue development and homeostasis. In response
to slightly stressful stimuli, cells usually start a cellular
stress response including DNA repair to ensure survival.
However, when irreversible damage accumulates, cells can
permanently arrest the cell cycle (cellular senescence) or
trigger a cell death program (apoptosis) [43].
ING1 is the founding member of the ING family and the
most well studied. Paul et al. conﬁrmed that ING1 interacts
speciﬁcally with three proteins, p38MAPK, mammalian
JNK/p38MAP kinase (MEKK4), and RAD50, by utilizing a
cross-species (yeast, ﬂy, and human) bioinformatics-based
approach. Both p38MAPK and MEKK4 participate in a
well-deﬁned stress response pathway. These novel ING-
interacting proteins further link ING proteins to cellular
stress and DNA damage signaling [44]. Nucleotide excision
repair (NER) is a crucial stress response mechanism for4 Journal of Oncology
maintaining genomic stability. Overexpression of p33ING1b
can enhance NER of both UV-damaged genomic DNA and
exogenous plasmid DNA in a host-cell-reactivation assay.
Moreover, p33ING1b requires the participation of functional
p53 in DNA repair and may be a crucial component in the
GADD45-mediatedNERpathway[45].Conversely,missense
mutations in the SAP30-interacting domain and PHD ﬁnger
motif of ING1 abrogated the enhancement of NER in a
host-cell-reactivationassayandaradioimmunoassay[46].In
addition, PCNA is an essential processivity factor for DNA
polymerases and functions in both eukaryotic chromosomal
DNA replication and NER. p33ING1b contains a PIP motif
within its N-terminus. By competitively binding PCNA
through its PIP domain, p33ING1b may contribute to regu-
lating the switch from DNA replication to DNA repair [47].
In both normal human epithelial keratinocytes (NHEKs)
and a keratinocyte cell line, HaCaT, the expression levels
of p33ING1b were elevated by UV induction independent of
p53 status, thus suggesting that ING1 may participate in
the cellular stress response and skin carcinogenesis [48]. In
addition, ING2 interacted with certain HAT or HDAC pro-
teins through its LZL domain, instead of the PHD region, to
regulate histone H4 acetylation, chromatin decondensation,
and NER [35]. Therefore, ING proteins may participate in
DNA repair through the regulation of the NER pathway in
response to cellular stress and DNA damage.
6. ING ProteinsandCell Cycle
Loss of proper control of the cell cycle is a major cause of cell
transformation. Cellular senescence refers to the arrest in the
G0 phase of the cell cycle [49]. p33ING1b was upregulated in
senescent human ﬁbroblasts, and antisense p33ING1b extends
the proliferative lifespan of normal human ﬁbroblasts [50].
Moreover, ectopic expression of ING1 in diploid human
ﬁbroblasts resulted in cell cycle arrest with some features
of cellular senescence [51]. Chromatin immunoprecipitation
analysis indicated that the chromatin binding aﬃnity of
p33ING1b was higher in senescent cells compared with young
cells, thus suggesting that ING1-mediated functions may be
subject to age-dependent mechanisms of control directed
to prevent induction of apoptosis in senescent but not in
young cells [52]. ING2 enhanced the interaction between
p53 and p300 and acted as a cofactor for p300-mediated p53
acetylation. Overexpression of ING2 induced senescence in
young ﬁbroblasts in a p53-dependent manner. Conversely,
the downregulation of ING2 expression by siRNA transfec-
tion led to delaying the onset of senescence [53].
Previous research has demonstrated that overexpression
of p33ING1b increased the number of human diploid ﬁbrob-
lasts in the G0/G1 phase. Conversely, antisense p33ING1b
permitted these cells to enter S phase [9]. Cyclin E is a
member of the cyclin family and binds to Cdk2 in the
G1 phase, which is required for the transition from G1 to
S phase. Expression of p33ING1b in human hepatocellular
carcinoma (HCC) was inversely correlated with cyclin E
kinase activity by autoradiography [54], thus implicating
that the reduction of p33ING1b expression may contribute
to the process of malignant transformation of HCC via an
increase of cyclin E kinase activity. Another study indicated
that ectopic expression of ING1b in H1299 cells sensitized
thecellstoshort-termG2/Mcellcycledelay[55].Inaddition,
adenovirus-mediated overexpression of ING1 in mouse
mammary epithelial cells resulted in the downregulation of
cyclin B1, which accumulates during the G2-M phase of
the cell cycle [55]. Moreover, adenovirus-ING4-mediated
transfection of PANC-1 human pancreatic carcinoma cells
inhibited cell growth, altered the cell cycle with S-phase
reduction and G2/M phase arrest, and induced apoptosis
[56]. These ﬁndings suggest that ING may regulate cell
senescenceandcellcycleviatheG1/SandtheG2/Mcellcycle
checkpoints.
7.INGand Apoptosis
Apoptosis plays important roles in normal development
and removal of the cells carrying severe DNA-damages
induced by DNA damaging agents. In cancer cells, activation
of pathways that favor cell survival instead of apoptosis
may contribute to tumorigenesis. Many diﬀerent agents
and growth environmental factors can be used to induce
apoptosis, such as cytotoxic drugs, irradiation, and serum
starvation.ExpressionofING1increasedupontheinduction
of apoptosis in P19 mouse teratocarcinoma cells by serum
deprivation. Elevated expression of ING1 cooperated with
c-myc gene expression to enhance the extent of apoptosis
in P19 and rodent ﬁbroblast cells [57]. Ectopic expression
of p33ING1b also sensitized cells to apoptosis induced by
etoposide, taxol, and doxorubicin [24, 52, 55]. Ectopic
expression of p33ING1b,b u tn o tp 4 7 ING1a, signiﬁcantly
enhanced UV- or hydrogen peroxide-induced apoptosis in
young (low passage) but not senescent Hs68 cells. Moreover,
cotransfection of p33ING1b and p53 increased the percentage
of apoptotic cells compared to transfection of either of
these two proteins alone [52]. Conversely, expression of
p33ING1b antisense constructs protects cells against apoptosis
[57] and promotes neoplastic transformation [9]. p33ING1b
activates transcription of the p21/WAF1 promoter, a key
mechanism required for p53-mediated cell growth control
[58]. Adenovirus-mediated transfer of p33ING1b with p53
suggested an additive or synergistic eﬀect on apoptosis in
immortal human cancer cells [59]. In addition, p33ING1b was
demonstrated to inﬂuence tumor necrosis factor (TNF)-α-
mediated apoptosis in Hs68 cell by upregulation of HSP70
expression and enhancement of the ability of TNF-α [60].
All ING proteins tested to date show the ability to regulate
apoptosis in varying degrees through similar or diﬀerent
signalpathways.Forexample,theING2PHDﬁngerinteracts
with phosphatidylinositol 5-phosphate (PtdIns5P) in vivo,
and their interaction regulates the ability of ING2 to activate
p53 and p53-dependent apoptotic pathways [61]. Increased
ING2 expression was also found to increase Bax expression
and enhance UVB-induced apoptosis in human melanoma
cells [62]. Additionally, overexpression of ING3 signiﬁcantly
promoted UV-induced apoptosis through the activation
of the Fas/caspase-8 pathway, and knockdown of ING3Journal of Oncology 5
remarkably decreased UV-induced apoptosis [63]. These
results suggested that ING might induce apoptosis through
varied pathways in response to diﬀerent agents.
8. ING and p53
p53 is an important TSG that is inactivated in many cancers.
p53 assimilates disparate input signals, including oncogene
activation, DNA damage, mitotic impairment, and oxidative
stress, to initiate appropriate outputs such as initiation of
DNA repair, cell cycle arrest, senescence, or apoptosis [64].
The physical and functional interactions between ING and
p53 have been investigated widely, but the conclusions are
not consistent. In overexpression experiments, all ING pro-
teinsexceptING3havebeenobservedtocoimmunoprecipate
with p53. Moreover, ING-induced cell cycle arrest and apop-
tosis were compromised in p53-deﬁcient cultured cells [25,
65, 66]. Functional p53 is required for p33ING1b-mediated
inhibition of cell growth in cultured cells. Furthermore,
p33ING1b was proposed to compete with murine double
minute 2 (MDM2), an important negative regulator of p53,
for the same binding site on p53, leading to an increase in
the stability and activity of p53 [67]. ING2 may modulate
p53-dependent chromatin remodeling, apoptosis, and DNA
repair by functioning as a scaﬀold protein to mediate the
interaction between p53 and p300 [35]. Additionally, over-
expression of ING4 or ING5 leads to a reduction in colony-
forming eﬃciency, inhibition of S-phase, and induction of
apoptosis in a p53-dependent manner. ING4 and ING5 may
stabilize p53 and enhance p53-mediated cellular responses
to genotoxic stresses and apoptotic stimuli through ING4/5-
mediated acetylation of p53 [13]. These results implicated
that ING proteins may be signiﬁcant modulators of p53
function. However, it was worth noting that the experiments
of ING1 knockout mice and knockout cells indicated that
ING1 functions were mostly independent from the p53
signaling pathway in physiological conditions [68, 69]. In
mice,theIng1 genedecodesthreesplicedisoforms.Ing1aand
Ing1c encode a 31kDa protein, and Inglb encodes a 37kDa
protein (p33ING1b in human). Loss of p37Ing1 induced BAX
expression and increased DNA damage-induced apoptosis in
primary cells and mice irrespective of p53 status. Moreover,
p53 functions are unperturbed in p37Ing1-deﬁcient cells.
Moreover, p37Ing1 suppressed the formation of spontaneous
follicular B-cell lymphomas in mice. Therefore, p37Ing1 can
negatively regulate cell growth, apoptosis, and tumorigenesis
in a p53-independent manner [69]. Previous studies also
demonstrated that the expression of ING might be inde-
pendent on p53 status in some tumor tissues. Decreased
ING1 expression may play important roles in tumorigenesis
of the specimens with expression of the wild-type p53 gene
in gastric carcinoma [70] and nonsmall cell lung carcinoma
(NSCLC) [71].
In addition, ING proteins are found to function in
a p53-independent manner. One major p53-independent
function of ING proteins may be negative regulation of NF-
κB. p33ING1b a n dI N G 2p r o t e i n sw e r ef o u n dt os u p p r e s s
expression of NF-κB by upregulating HSP70 gene expression
and augment TNF-α-induced apoptosis [60]. ING4 is shown
to directly interact with p65(RelA) in glioma cells to
inhibit transcriptional activity of NF-κB. Correspondingly,
the expression of NF-κB-responsive genes is shown to be sig-
niﬁcantly increased in ING4 knockdown cells [72]. Another
study showed that ING4 suppresses NF-κB-regulated pro-
moters by binding with both of p65 and H3K4me3 on the
promoter [73]. This recruitment of ING4 accompanies the
reduction of p65 phosphorylation and concomitant change
of complex formation of p65 with p300 (HAT) to HDAC1
resultinginthedecreaseofacetylatedhistonesandH3K4me3
within the promoter [73]. Additionally, ING4 was found to
aﬀect the stability of hypoxia inducible factor (HIF) and
mediate HIF activity [72].
Based on these ﬁndings, ING and p53 may function
independently in apoptosis pathways, but they can inﬂuence
theactivityofeachotherintumorigenesis[15].Asepigenetic
regulators of chromatin structure, ING proteins may amplify
the eﬀects of p53 on gene expression and also directly aﬀect
DNA repair and apoptosis independently of p53 by altering
chromatin structure.
9. ING Genes and Tumorigenesis
Previous studies have implicated members of the ING
family as candidate type II TSGs that are involved in
a variety of processes, including DNA repair, cell cycle
control, senescence, apoptosis, and chromatin remodeling,
which are critical points for genomic integrity and stability
(Figure 2) .Th u s ,l o s so rd ec r e a s eo fI N Ge x p r e s s i o nm a ybea
potential key point in tumorigenesis. Knockout experiments
demonstrated that ing1-diﬁcient mice were more sensitive to
total body gamma radiation, and loss of ing1 was associated
with earlier onset and higher incidence of lymphomas
[68].
Loss of nuclear p33ING1b was observed in melanoma,
seminoma, papillary thyroid carcinoma, ductal breast car-
cinoma, and acute lymphoblastic leukemia by comparing
these neoplastic tissues with normal cells and tissues [74].
Until now, inactivation and reduced expression of ING
genes has been reported in cancers of lung [71], breast
[75], stomach [70, 76], esophagus [77], blood [78], brain
[79], and HNSCC [80]. Interestingly, ING gene mutation is
uncommon in cancer. In fact, translocation of ING proteins
from the nucleus to the cytoplasm has been observed in
some types of cancer, such as the tumors of the breast [75]
and brain [79], melanoma [74], and lymphoblastic leukemia
[78].Therefore,theINGcellularcompartmentshiftfromthe
n u c l e u st ot h ec y t o p l a s mm a yc a u s el o s so fn o r m a lc e l l u l a r
function and may play a central role in tumorigenesis and
progression.
Like other ING genes, nonphysiological overexpression
of ING2 induces apoptosis and cell cycle arrest via p53
modiﬁcation[10],anddecreasedING2expressionwasfound
incutaneouscancer[81]andHNSCC[82].However,expres-
sion of ING2 was upregulated in colorectal cancer [83],
Burkitt’s lymphoma, and cervical cancer [29]. Moreover,
ING2 may bind to the RPB1-mSin3A-HDAC complex on the6 Journal of Oncology
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Figure 2: The role of p33ING1b protein in tumor supression. p33ING1b could recognize trimethylated lysine 4 of histone H3 (H3K4me3)
by PHD domain and has been implicated in chromatin remodeling and activation of some genes transcription. This binding is somehow
necessary for induction of DNA repair and cell death. p33ING1b also associates with the Sin3/HDAC-mediated transcriptional repression
through its unique N-terminal sequence and may be involved in repression of some essential cell cycle regulator genes. Moreover, p33ING1b
binds PCNA and p300 complex to promote DNA repair through a PIP motif in response to UV-irradiation and, subsequently, may trigger
apoptosisbytheinductionofp21expression.p33ING1b competeswithmurinedoubleminute2(MDM2)leadingtoanincreaseinthestability
and activity of p53. p21, the one of the targets of p53, is also upregulated to involve in cell cycle arrest and the induction of apoptosis.
Additionally, p33ING1b could upregulate expression of HSP70 gene to induce apoptosis independently of p53 status. Furthermore, p33ING1b
binds to lamin A via LID domain to stabilize its level and biological function in nucleus. Conversely, 14-3-3 can bind to p33ING1b with
phosphorylated serine 199 and results in translocation of p33ING1b from the nucleus to the cytoplasm, which may involve in tumorigenesis.
MMP13 promoter to upregulate MMP-13 expression [83].
Thus, the function of ING2 may be diﬀerent depending on
thecancertype.ArecentstudysuggestedthatING2isanovel
mediator of transforming growth factor (TGF)-β-dependent
responses in epithelial cells [84]. TGF-β is considered to have
tumor suppressor-like functions in normal epithelium and
also have oncogenic functions in invasive metastatic cancers.
Therefore, ING2 may play diﬀerent roles in normal cells and
cancers by mediating the TGF-β signaling pathway.
10. Expressionof ING Genes in HNSCC
Previous studies have demonstrated 45.5%–68% LOH of
ING genes in HNSCC (Table 1), and 50%–76% decreases
in the mRNA levels of ING3–5. In recent studies, we also
investigated expression as well as the subcellular localization
of ING proteins in 214 cases of HNSCC by immunohis-
tochemistry. Decreased expression of p33ING1b,I N G 4 ,a n d
ING5 in nuclei was observed in 36.9%, 61.3%, and 36%
of the HNSCC cases, respectively. These results suggest
that the loss or downregulation of nuclear expression of
ING proteins participates in tumorigenesis of HNSCC. By
contrast, mutations of the ING genes are rare (0–4.3%) in
HNSCC although most of the mutations are present in the
domains critical for the functions of ING proteins (Table 1),
suggesting that mutations are not the major cause for ING
family inactivation. In addition, the shift of p33ING1b from
the nucleus to the cytoplasm was observed in 24.5% of 49 in
oral SCCs [85]. In our studies, aberrant cytoplasmic expres-
sion of p33ING1b, ING4, and ING5 was detected in 14.5%,
68.8%, and 47.7% in 214 cases of HNSCC, respectively [80,
86, 87], while no or seldom cytoplasmic expression of these
ING proteins was detectable in the cases of normal mucosa.Journal of Oncology 7
Table 1: ING gene mutation and expression in HNSCC.
ING Origin Methods Mutation
type/expression change Position Frequency Reference
ING1
Patient MM LOH 13q34 20/44(45.5%) [88]
Cell lines Sequencing No mutation 0/5
Patient Sequencing No mutation 0/20
Patient MM LOH 13q33-34 23/34(68%) [89]
Patient PCR-SSCP Missense PHD (215) 1/23(4.3%)
Patient PCR-SSCP Missense PHD (216) 1/23(4.3%)
Patient PCR-SSCP Missense NLS (192) 1/23(4.3%)
Patient RT-PCR Downregulation 6/12(50%) [90]
Patient IHC Downregulation 37/49(76%) [85]
Cell lines Sequencing No mutation 0/3 [86]
Patient IHC Downregulation 79/214(36.9%)
ING2 Patient MM LOH 4q35.1 33/55(54.6%) [82]
ING3
Patient MM LOH 7q31 22/46(48%) [91]
Patient RT-PCR Downregulation 20/40(50%)
Patient PCR-SSCP Missense LZL(20) 1/49(2%)
Patient RT-PCR Downregulation 37/71(52.1%) [92]
Patient RT-PCR Upregulation 15/71(21%)
ING4
Patient MM LOH 12p13 33/50(66%) [87]
Patient Sequencing No mutation 0/50
Patient Q-PCR Downregulation 38/50(76%)
Patient Q-PCR Upregulation 7/50(14%)
Cell lines Sequencing No mutation 0/3 [93]
Patient IHC Downregulation 96/214(44.9%)
ING5
Patient RT-PCR Downregulation 19/31(61.3%) [94]
Patient Sequencing Missense LZL(33) 1/31(3.2%)
Patient Sequencing Missense NCR(68) 1/31(3.2%)
Patient Sequencing Missense NCR(74) 1/31(3.2%)
Cell lines Sequencing No mutation 0/3 [80]
Patient IHC Downregulation 77/214(36%)
Note: MM, Microsatellite marker; PCR-SSCP, Polymerase chain reaction-single strand conformation polymorphism; RT-PCR, Retrotranscription-
polymerase chain reaction; Q-PCR, Quantitative-polymerase chain reaction; IHC, immunohistochemistry.
Nuclear localization of ING proteins is required for their
normal function. Therefore, decreased nuclear expression
of ING proteins, through either downregulation of nuclear
expression or relocation from the nucleus to cytoplasm, may
play a crucial role in the development and progression of
HNSCC (Figure 3) and may be a new biomarker for the
tumorigenesis of HNSCC.
The mechanism of translocation of ING proteins is
not fully understood. Recently, a study from Riabowol’s
group demonstrated that p33ING1b can especially bind
members of the 14-3-3 family through phosphorylation
at serine residue 199 [28]. 14-3-3 family members pri-
marily reside in the cytoplasm and are associated with
phosphorylated ligands involved in many cellular processes,
including regulation of the cell cycle and DNA damage
Normal squamous
epithelium
Dysplastic
epithelium
Invasive squamous
cell carcinoma
Figure 3: The schematic diagram of ING proteins expression
in the malignant development of HNSCC. Nuclear expression of
ING proteins is downregulated from normal squamous epithelium
to dysplastic epithelium and invasive HNSCC. In contrast, the
cytoplasmic expression of ING proteins in dysplastic epithelium
and invasive HNSCC is gradually increased compared with normal
squamous epithelium. The positive expression of ING proteins is
shown with brown color.8 Journal of Oncology
checkpoints [95]. 14-3-3 binding results in tethering of
signiﬁcant amounts of p33ING1b in the cytoplasm [28].
Additionally, cytoplasmic p33ING1b could be imported into
the nucleus through interactions between its intrinsic NLS
and karyopherins α2a n dβ1[ 96]. In the nucleus, lamin
A binds and targets ING1 and regulates ING1 levels and
biological function [27]. Therefore, 14-3-3, karyopherins α2
and β1, and lamin A are involved in the dynamic regulation
of subcellular distribution of ING1. Recently, we investigated
the expression of p33ING1b and 14-3-3η in 214 cases of
HNSCC by immunohistochemistry and found that cytoplas-
mic p33ING1b expression was signiﬁcantly associated with
14-3-3η expression. Moreover, double immunoﬂuorescence
results conﬁrmed the coexpression of p33ING1b and 14-3-
3η (unpublished data). These data indicated that 14-3-3η
plays an important role in the cytoplasmic accumulation of
p33ING1b in HNSCC. However, the function of cytoplasmic
ING is unclear and needs to be further studied.
There have been a few studies on the correlation
between clinicopathological variables and expression of the
ING genes. High LOH frequency of ING2 was statistically
associated with advanced T stage, suggesting that ING2 LOH
might occur at the late stage of HNSCC progression [82].
Although no clinicopathological variables were signiﬁcantly
related to the levels of ING3 mRNA, decreased expression
of ING3 mRNA was associated with high mortality and was
an independent prognostic factor for poor overall survival
[92]. In our recent studies, no signiﬁcant correlation was
found between high nuclear expression of p33ING1b and
clinicopathological variables in HNSCC, but high expression
of cytoplasmic p33ING1b was signiﬁcantly correlated with
poor diﬀerentiation, T staging, lymph node metastasis, and
TNM staging [86]. Also, high expression of nuclear ING4 in
HNSCC was negatively correlated with poor diﬀerentiation,
T staging, and TNM staging, while high expression of
cytoplasmic ING4 in HNSCC was positively correlated with
l y m p hn o d em e t a s t a s i s[ 93]. Also in the case of ING5,
its nuclear expression correlated with diﬀerentiation of
HNSCC, and abundant cytoplasmic expression correlated
with poor diﬀerentiation [80].
11. Conclusions
The ING family genes are supposed to belong to type II
TSG and are involved in multiple cellular processes includ-
ing chromatin remodeling, DNA repair, cell cycle control,
senescence, and apoptosis. ING proteins are expressed inde-
pendently of p53 status and function in both p53-dependent
and p53-independent manner. Loss or downregulation of
ING genes expression and/or translocation of ING proteins
from the nucleus to the cytoplasm may play an important
role in neoplastic development of HNSCC. Thus, the ING
gene family could be a novel p53-independent biomarker
for HNSCC. Further elucidation of the functions of ING
family proteins, which can be either tumor suppressive
or tumorigenic, will rationalize their application for a
biomarker, and it will also reveal the potentiality of ING
proteins as the therapeutic target [97].
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